Results 71 to 80 of about 55,188 (97)

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Journal of Clinical Oncology, 2005
S. Chan, M. Scheulen, S. Johnston, K. Mross, F. Cardoso, C. Dittrich, W. Eiermann, D. Hess, R. Morant, V. Semiglazov, M. Borner, M. Salzberg, V. Ostapenko, H. Illiger, D. Behringer, N. Bardy-Bouxin, J. Boni, S. Kong, M. Cincotta, L. Moore   +19 more
semanticscholar   +1 more source

Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.

Journal of Clinical Oncology, 2011
C. Hofmeister, Xiaoxia Yang, F. Pichiorri, Ping Chen, Darlene M. Rozewski, A. Johnson, Seungsoo Lee, Zhongfa Liu, C. Garr, E. Hade, Jia Ji, L. Schaaf, D. Benson, E. Kraut, W. Hicks, K. Chan, Ching S. Chen, S. Farag, M. Grever, J. Byrd, M. Phelps   +20 more
semanticscholar   +1 more source

Exploring the optimal indwelling pleural catheter drainage technique in India

Lung India
Vikas Marwah, Robin Choudhary
doaj   +1 more source

CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability.

Cancer Research, 2011
Hongyan Wang, Chun-Peng Zhang, A. Rorick, Dayong Wu, Ming Chiu, J. Thomas-Ahner, Zhong Chen, Hongyan Chen, S. Clinton, K. Chan, Qianben Wang   +10 more
semanticscholar   +1 more source

A young lady with multiple lung nodules

Lung India
Afshan Shaik, Mahismita Patro, Ranjan Patel, Aswathy Girija, Sourin Bhuniya   +4 more
doaj   +1 more source

A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas

Cancer, 2011
S. Okuno, H. Bailey, M. Mahoney, D. Adkins, W. Maples, T. Fitch, D. Ettinger, C. Erlichman, J. Sarkaria   +8 more
semanticscholar   +1 more source

mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer.

Endocrine-Related Cancer, 2001
Ker Yu, L. Toral‐Barza, C. Discafani, Weiguo Zhang, J. Skotnicki, P. Frost, James Joseph Gibbons   +6 more
semanticscholar   +1 more source

Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks

Clinical Cancer Research, 2010
J. Sarkaria, E. Galanis, Wenting Wu, A. Dietz, T. Kaufmann, M. Gustafson, P. Brown, J. Uhm, R. Rao, L. Doyle, C. Giannini, K. Jaeckle, J. Buckner   +12 more
semanticscholar   +1 more source

Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation.

Blood, 2010
K. Friedbichler, M. Kerenyi, B. Kovacic, Geqiang Li, Andrea Hoelbl, Saliha Yahiaoui, V. Sexl, E. Müllner, Sabine Fajmann, S. Cerny‐Reiterer, P. Valent, H. Beug, F. Gouilleux, K. Bunting, R. Moriggl   +14 more
semanticscholar   +1 more source

Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma

Molecular Cancer Therapeutics, 2009
O. Ekshyyan, Y. Rong, Xiaohua Rong, K. Pattani, F. Abreo, G. Caldito, John Kai Siung Chang, F. Ampil, J. Glass, C. Nathan   +9 more
semanticscholar   +1 more source